According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 5.7% and a 38.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $88.91.
Based on Incyte’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $863 million and net profit of $564 million. In comparison, last year the company earned revenue of $790 million and had a net profit of $150 million.
Based on the recent corporate insider activity of 105 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY: